Regeneron Pharmaceuticals Inc (NASDAQ:REGN) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 2,050,000 shares, a growth of 28.1% from the September 15th total of 1,600,000 shares. Approximately 2.0% of the shares of the stock are sold short. Based on an average daily volume of 842,700 shares, the short-interest ratio is presently 2.4 days.
In related news, SVP Marion Mccourt sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, October 5th. The stock was sold at an average price of $600.00, for a total transaction of $600,000.00. Following the transaction, the senior vice president now directly owns 14,963 shares of the company's stock, valued at $8,977,800. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, VP Christopher R. Fenimore sold 3,709 shares of the business's stock in a transaction dated Tuesday, July 21st. The stock was sold at an average price of $642.04, for a total transaction of $2,381,326.36. Following the completion of the sale, the vice president now owns 25,277 shares in the company, valued at $16,228,845.08. The disclosure for this sale can be found here. Insiders sold 168,923 shares of company stock valued at $101,670,609 over the last 90 days. 11.28% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in REGN. FMR LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 47.2% during the 2nd quarter. FMR LLC now owns 12,463,480 shares of the biopharmaceutical company's stock worth $7,772,849,000 after buying an additional 3,999,170 shares during the period. BlackRock Inc. grew its position in shares of Regeneron Pharmaceuticals by 48.4% in the second quarter. BlackRock Inc. now owns 9,789,573 shares of the biopharmaceutical company's stock valued at $6,105,267,000 after purchasing an additional 3,191,724 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Regeneron Pharmaceuticals by 22.3% in the second quarter. Vanguard Group Inc. now owns 7,844,995 shares of the biopharmaceutical company's stock valued at $4,892,530,000 after purchasing an additional 1,429,765 shares during the last quarter. State Street Corp increased its stake in shares of Regeneron Pharmaceuticals by 1.2% in the first quarter. State Street Corp now owns 3,617,333 shares of the biopharmaceutical company's stock worth $1,766,308,000 after purchasing an additional 43,216 shares during the period. Finally, Nuveen Asset Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 40.5% during the 2nd quarter. Nuveen Asset Management LLC now owns 1,706,789 shares of the biopharmaceutical company's stock worth $1,064,438,000 after purchasing an additional 492,173 shares during the last quarter. 85.89% of the stock is currently owned by institutional investors.
Regeneron Pharmaceuticals stock traded up $14.56 during mid-day trading on Friday, hitting $599.74. 1,169,004 shares of the company's stock were exchanged, compared to its average volume of 1,162,364. Regeneron Pharmaceuticals has a 1-year low of $294.86 and a 1-year high of $664.64. The stock has a 50 day moving average of $578.51 and a two-hundred day moving average of $585.04. The company has a current ratio of 2.12, a quick ratio of 1.68 and a debt-to-equity ratio of 0.08. The stock has a market cap of $63.81 billion, a P/E ratio of 23.22, a P/E/G ratio of 1.43 and a beta of 0.50.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported $7.16 EPS for the quarter, beating the Zacks' consensus estimate of $5.59 by $1.57. Regeneron Pharmaceuticals had a return on equity of 26.71% and a net margin of 37.30%. The business had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.74 billion. During the same quarter in the prior year, the firm posted $6.02 EPS. The firm's revenue for the quarter was up 23.7% on a year-over-year basis. As a group, research analysts predict that Regeneron Pharmaceuticals will post 28.16 EPS for the current fiscal year.
A number of brokerages recently weighed in on REGN. Piper Sandler raised their target price on shares of Regeneron Pharmaceuticals from $630.00 to $675.00 and gave the stock an "overweight" rating in a report on Wednesday, August 5th. BMO Capital Markets lifted their target price on Regeneron Pharmaceuticals from $525.00 to $626.00 and gave the stock an "outperform" rating in a report on Thursday, August 6th. ValuEngine lowered Regeneron Pharmaceuticals from a "hold" rating to a "sell" rating in a research report on Friday, September 11th. Oppenheimer lifted their price target on Regeneron Pharmaceuticals from $675.00 to $725.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. Finally, Goldman Sachs Group upped their price objective on shares of Regeneron Pharmaceuticals from $700.00 to $800.00 in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Regeneron Pharmaceuticals currently has an average rating of "Buy" and an average target price of $611.64.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: What is a Swap?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
20 Stocks Analysts Can't Stop Upgrading
As you know, a single upgrade from a broker probably won't be a major game changer for any single stock. But, what if there was a stock that had been upgraded by more than 10 different brokers during the last 90 days?
If ten different brokers have all upgraded a stock within the last few months and the price hasn't skyrocketed (at least, not yet), you would want to take a pretty hard look at it.
It turns out that there are actually 20 different companies that have been upgraded or had their price target increased at least ten times during the last ninety days by more than 10 different brokers. This slideshow lists those companies.
View the "20 Stocks Analysts Can't Stop Upgrading".